Agree, there are some positives like the below:
Penetration continues to increase, with approximately 30% of the 5,000 diagnosed patients having initiated therapy. In market research, physicians surveyed stated that over the next 24 months they expect to expand prescribing to more than 70% of their eligible patients.
Once the FDA meeting is completed in September, and hopefully further indications announced the Board just needs to wrap a bow around the company.
Agree, there are some positives like the below:Penetration...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.63 |
Change
-1.080(6.46%) |
Mkt cap ! $1.997B | |||
| Open | High | Low | Value | Volume |
| $16.61 | $16.65 | $15.54 | $8.354M | 529.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 830 | $15.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.74 | 1484 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |